Home / Author / Karen Rowland Yeo, PhD

Karen Rowland Yeo, PhD

Senior Vice President, Client & Regulatory Strategy

Since 2002, Karen has led projects relating to the extrapolation of in vitro data to predict in vivo pharmacokinetics in humans. This has included development and implementation of the models into the Simcyp Simulator. Her specific research interests include physiologically based pharmacokinetic modeling and prediction of drug-drug interactions.

Authored by Karen Rowland Yeo, PhD

Karen Rowland Yeo, PhD

An Endogenous Biomarker for Predicting OATP1B DDIs

Is your Drug-Drug Interactions package up to date with ICH guidelines?

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The Role of PBPK Modeling & Simulation in Infants & Neonates

5 Tips for Authoring an Investigator’s Brochure Summary of Changes

How to Accelerate and Streamline Cell & Gene Therapy Development

How to Navigate the Increasingly Stormy Waters of Accessing US Managed Markets

Getting Gene Therapies to Patients

Formulary Decision Making: Must Have Instruments in Value Translation

Prescription Drug Pricing: “The Times They Are A-Changin”